Post-statin approaches to hyperlipidaemia

Bibliography

• SHEPHERD J, COBBE SM, FORD I et al.: Prevention ofcoronary heart disease with pravastatin in men with hypercholesterolemia. New Engl. J. Med. (1995) 333:1301–1307.
   PubMed Web of Science ®Google Scholar
• PEDERSEN TR, KJEKSHUS J, BERG K et al.: Randomisedtrial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383–1389.
   PubMed Web of Science ®Google Scholar
• FRICK MH, ELO O, HAAPA K etal: Helsinki Heart Study:primary-prevention trial with gemflbrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. New Engl.J. Med. (1987) 317:1237–1245.
   Google Scholar
• ERICSSON CG, HAMSTEN A, NILSSON J et al: Angio-graphic assessment of effects of bezaflbrate on pro-gression of coronary artery disease in young male postinfarction patients. Lancet (1996) 347:849–853.
   PubMed Web of Science ®Google Scholar
• SACKS FM, PFEFFER MA, MOYE LA etal: The effect of pra-vastatin on coronary events after myocardial infarc-tion in patients with average cholesterol levels. New Engl. J. Med. (1996) 335 :1001–1009 .
   PubMed Web of Science ®Google Scholar
• BAKKERARKEMA RG, DAVIDSON MH, GOLDSTEIN RJ et al.: Efficacy and safety of a new HMG-CoA reductase in-hibitor, atorvastatin, in patients with hypertriglyc-eridemia. JAMA (1996) 275:128–133.
   PubMed Web of Science ®Google Scholar
• OOI TC, HEINONEN T, ALAUPOVIC P et al.: Efficacy and safety of a new hydroxymethylglutaryl-coenzyme a re-ductase inhibitor, atorvastatin, in patients with com-bined hyperlipidemia: comparison with fenoflbrate. Arterioscler. Thromb. Vasc. Biol. (1997) 17:1793–1799.
   Google Scholar
• MATSUDA K: ACAT inhibitors as antiatheroscleroticagents: compounds and mechanisms. Med. Res. Rev. (1994) 14:271–305.
   PubMed Web of Science ®Google Scholar
• NATORI S, OKAZAKI Y, NAKAJIMA T, HIROHASHI T, AONO S: Mechanism of the inhibition of cholesterol absorption by DL-melinamide: inhibition of choles-terol esterification. Jpn.J. Pharmacol (1996) 42:517–523.
   Google Scholar
• KUSUNOKI J, ARAGANE K, YAMAURA T, OHNISHI H: Studies on acyl-CoA: cholesterol acyltransferase (ACAT) inhibitory effects and enzyme selectivity of F-1394, a pantotheic acid derivative. Jpn. J. Pharmacol (1995) 67:195–203.
   PubMedGoogle Scholar
• KUSUNOKI J, ARAGANE K, KITAMINE T etal.: A potent in-hibitor of acyl-CoA:cholesterol acyltransferase (ACAT), F-1394 accelerates the cholesterol efflux from foam cells. 12th Int. Symp. on Drugs Affect. Lipid Metab. Houston (1995).
   Google Scholar
• KUSUNOKI J AKKTYTOH: F-1394 a potent acyl-CoA cho-lesterol acyltransferase (ACAT) inhibitor, prevents ACAT-mediated absorption on cholesterol via guts. Jpn. Pharmacol. (1995) 67:1–45.
   PubMedGoogle Scholar
• KUSUNOKI J, ARAGANE K, KITAMINE T et al.: Hypocho-lesterolemic action and prevention of cholesterol ab-sorption via the gut by F-1394, a potent acyl-CoA:cholesterol acyltransferase (ACAT) inhibi-tor, in cholesterol diet-fed rats. Jpn. j Pharmacol. (1995) 69:53–60.
   PubMedGoogle Scholar
• YAMASHITA J, ISLAM A, ISHIGAMI M et al: Effects on a novel ACAT inhibitor F-1394 on the progression and regression of atherosclerotic lesions in the aorta of cholesterol-fed rabbits. 12th Int. Symp. on Drugs Affect. Lipid Metab. Houston (1995).
   Google Scholar
• RAMHARACK R, SPAHR MA, SEKERKE CS et al.: CI-1011 lowers lipoprotein(a) and plasma cholesterol concen-trations in chow-fed cynomolgus monkeys. Atheroscle-rosis (1998) 136:79–87.
   PubMed Web of Science ®Google Scholar
• KRAUSE BR, HOMAN R, BOCAN TMA et al: CI-1011: un-expected preclinical pharmacological profile for an ACAT inhibitor. 66th Congr. Eur. Atheroscler. Soc. Flor-ence (1996).
   Google Scholar
• KRAUSE BR, PAPE M, REA T et al.: CI-1011: a novel cholesterol-lowering compound in both chow-fed and cholesterol-fed rodent and nonrodent species. 12th Int. Symp. on Drugs Affect. Lipid Metab. Houston (1995).
   Google Scholar
• AUERBACH BJ, BOUSLEY RF, STANFIELD RL et al.: Modu-lation of apo B kinetics and lipoprotein cholesterol in the casein-fed rabbit by CI-1011. 12th Int. Symp. on Drugs Affect. Lipid Metab. Houston (1995).
   Google Scholar
• LEE HT, PICARD JA, SLISKOVIC DR et al: CI-1011: a po-tent lipid regulating agent. 12th Int. Symp. on Drugs Af-fect. Lipid Metab. Houston (1995).
   Google Scholar
• HUT YF, MILAD MA, ROBERTSON DG, LATHIA CD: Phar-macokinetics and pharmacodynamics in a 2-week study in beagle dogs of CI-1011, an in vivoACAT inhibi-tor. 12th Int. Symp. on Drugs Affect. Lipid Metab. Houston (1995).
   Google Scholar
• BOCAN TMA, ROSEBURY WS, BAKMUELLER S et al.: CI-1011, an ACAT inhibitor with paradoxical antiathero-sclerotic activity. 12th Int. Symp. on Drugs Affect. Lipid Metab. Houston 1995.
   Google Scholar
• MILAD M, ROBERTSON D, LATHIA C: Single and multiple dose pharmacokinetics in dogs of CI-1011, an in vivo ACAT inhibitor. 12th Int. Symp. on Drugs Affect. Lipid Me-tab. Houston (1995).
   Google Scholar
• LATHIA C, ROBERTSON D, MILAD M: Single and multiple dose pharmacokinetics of CI-1011, an in vivo ACAT in-hibitor, in rat. 12th Int. Symp. on Drugs Affect. Lipid Metab. Houston (1995).
   Google Scholar
• BURNETT DA, CAPLEN MA, DAVIS HR, BURRIER RE, CLADER JW: 2-azetidinones as inhibitors of cholesterol absorption. J. Med. Chem. (1994) 37(12):1733–1736.
   PubMed Web of Science ®Google Scholar
• DUGAR S, KIRKUP MP, CLADER JW et al.: Gamma-lactams and related compounds as cholesterol absorption in-hibitors: homologs of the beta-lactam cholesterol ab-sorption inhibitor SC1148461. Bioorg. Med. Chem. Lett. (1995) 5(24):2947–2952.
   Web of Science ®Google Scholar
• SALISBURY BG, DAVIS HR, BURRIER RE et al.: Hypocho-lesterolemic activity of a novel inhibitor of cholesterol absorption, SC1148461. Atherosclerosis (1995) 115:45–63.
   PubMed Web of Science ®Google Scholar
• BURRIER R, SMITH A, MCGREGOR D, HOOS L, SYBERTZH: Effect of SCH48461 in intestinal cholesterol metabo-lism in the hamster. Atherosclerosis (1994) 109:163.
   Google Scholar
• HEEK MV, COMPTON D, FRANCE C et al.: Isolation and identification of the active metabolite(s) of SCH48461 and possible in vivo mechanism of action for their in-hibition of cholesterol absorption. 12th Int. Symp. on Drugs Affect. Lipid Metab. Houston (1995).
   Google Scholar
• CUTLER D, KOSOGLOU T, ALTON K et al: Effect of a high fat vs. non-fat meal on the bioavailability (BA) of SCH48461. Clin. Pharmacol. Ther. (1995) 57:36.
   Web of Science ®Google Scholar
• BERGMAN M, MORALES H, MELLARS L et al.: The clinical development of a novel cholesterol aborption inhibi-tor. 12th Int. Symp. on Drugs Affect. Lipid Metab. Houston (1995).
   Google Scholar
• ROARK WH, ROTH BD: ACAT inhibitors: preclinical profiles of clinical candidates. Exp. Opin. Invest. Drugs (1994) 4(10:1143–1152.
   Google Scholar
• HAWKE RL, CHAPMAN JM, WINEGAR DA etal.: Potent hy-pocholesterolemic activity of novel ureido phenoxyi-sobutyrates correlates with their intrinsic fibrate potency and not with their ACAT inhibitory activity. J. Lipid Res. (1997) 38:1189–1203.
   Google Scholar
• MUKHERJEE R, STRASSER J, JOWL et al.: RXR agonists ac-tivate PPAR alpha-inducible genes, lower triglycerides, and raise HDL levels in vivo. Arterioscler. Thromb. Vasc. Biol. (1998) 18:272–276.
   PubMed Web of Science ®Google Scholar
• MUKHERJEE R, DAVIES PJ, CROMBIE DL et al.: Sensitiza-tion of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature (1997) 386:407–410.
   PubMed Web of Science ®Google Scholar
• BISCHOFF ED, GOTTARDIS MM, MOON TE, HEYMAN RA,LAMPH WW: Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res. (1998) 58:479–484.
   PubMed Web of Science ®Google Scholar
• MILLER VA, BENEDETTI FM, RIGAS JR et al.: Initial clini-cal trial of a selective retinoid X receptor ligand, LGD1069. j Clin. Oncol. (1997) 15:790–795.
   PubMed Web of Science ®Google Scholar
• STAELS B, KOENIG W, HABIB A et al.: Activation of hu-man aortic smooth-muscle cells is inhibited by PPAR-alpha but not by PPARgamma activators. Nature (1998) 393:790–793.
   PubMed Web of Science ®Google Scholar
• HAGHPASSAND M, WILDER D, MOBERLY JB: Inhibition of apolipoprotein B and triglyceride secretion in hu-man hepatoma cells (HepG2). J. Lipid Res. (1996) 37:1468–1480.
   PubMed Web of Science ®Google Scholar
• GORDON DA, JAMIL H, GREGG RE, OLOFSSON SO, BOREN J: Inhibition of the microsomal triglyceride transfer protein blocks the first step of apolipoprotein B lipoprotein assembly but not the addition of bulk core lipids in the second step. J. Biol. Chem. (1996) 271:33047–33053.
   PubMed Web of Science ®Google Scholar
• BENOIST F, NICODEME E, GRANDPERRET T: Microsomal triacylglycerol transfer protein prevents presecretory degradation of apolipoprotein B-100 - a dithiothreitol-sensitive protease is involved. Eur. J. Bio-chem. (1996) 240:713–720.
   Web of Science ®Google Scholar
• RIMM EB, STAMPFER MJ, ASCHERIO A et al: Vitamin E consumption and the risk of coronary heart disease in men. New Engl. J. Med. (1993) 328:1450–1456.
   PubMed Web of Science ®Google Scholar
• STAMPFER MJ, HENNEKENS CH, MANSON JE et al.: Vita- min E consumption and the risk of coronary disease in women. New Engl. J. Merl. (1993) 328:1444–1449.
   PubMed Web of Science ®Google Scholar
• STEPHENS NG, PARSONS A, SCHOFIELD PM et al.: Ran- domised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet (1996) 347:781–786.
   PubMed Web of Science ®Google Scholar
• GROSSMAN M, RAPER SE, KOZARSKY K et al.: Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nature Genet. (1994) 6:335–341.
   PubMed Web of Science ®Google Scholar
• TSUKAMOTO K, HIESTER KG, SMITH P et al.: Compari-son of human apoA-I expression in mouse models of atherosclerosis after gene transfer using a second gen-eration adenovirus. J. Lipid Res. (1997) 38:1869–1876.
   PubMed Web of Science ®Google Scholar
• SEGURETMACE S, LATTAMAHIEU M, CASTRO G et al: Po-tential gene therapy for lecithin-cholesterol acyltrans-ferase (LCAT)-deficient and hypoalpha-lipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene. Circulation (1996) 94:2177–2184.
   PubMed Web of Science ®Google Scholar
• MILLER BD, ALDERMAN EL, HASKELL WL, FAIR JM, KRAUSS RM: Predominance of dense low-density lipo-protein particles predicts angiographic benefit of therapy in the stanford coronary risk intervention project. Circulation (1996) 94:2146–2153.
   PubMed Web of Science ®Google Scholar
• LAMARCHE B, TCHERNOF A, MOORJANI S et al.: Small,dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospec-tive results from the Quebec Cardiovascular Study. Cir-culation (1997) 95:69–75.
   PubMed Web of Science ®Google Scholar
• OKUNO A, TAMEMOTO H, TOBE K et al: Troglitazone in-creases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J. Clin. Invest. (1998) 101:1354–1361.
   PubMed Web of Science ®Google Scholar
• MUELLER E, SARRAF P, TONTONOZ P et al.: Terminal dif-ferentiation of human breast cancer through PPAR gamma. Mol. Cell. (1998) 1:465–470.
   PubMed Web of Science ®Google Scholar
• CARR A, SAMARAS K, CHISHOLM DJ, COOPER DA: Patho-genesis of HIV-1-protease inhibitor-associated periph-eral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet (1998) 351: 1881-1883.
   Google Scholar